|
gptkbp:instanceOf
|
gptkb:drug
carbonic anhydrase inhibitor
|
|
gptkbp:approvedBy
|
1953
|
|
gptkbp:ATCCode
|
S01EC01
|
|
gptkbp:bioavailability
|
100%
|
|
gptkbp:brand
|
gptkb:Diamox
|
|
gptkbp:CASNumber
|
59-66-5
|
|
gptkbp:chemicalClass
|
sulfonamide
|
|
gptkbp:contraindication
|
severe liver disease
sulfa allergy
adrenal gland failure
|
|
gptkbp:discoveredBy
|
gptkb:Bernard_B._Brodie
|
|
gptkbp:discoveredIn
|
1952
|
|
gptkbp:effect
|
decreases intracranial pressure
decreases intraocular pressure
induces diuresis
reduces production of aqueous humor
|
|
gptkbp:eliminationHalfLife
|
10-15 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
C4H6N4O3S2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
acetazolamide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits carbonic anhydrase enzyme
|
|
gptkbp:meltingPoint
|
258-259°C
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
1912
1986
CHEMBL24
DB00819
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
fatigue
metabolic acidosis
kidney stones
paresthesia
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:synonym
|
gptkb:N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide
|
|
gptkbp:UNII
|
O3FX965V0I
|
|
gptkbp:usedFor
|
gptkb:pseudotumor_cerebri
congestive heart failure
epilepsy
altitude sickness
glaucoma
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Soroche
gptkb:2C9V
|
|
gptkbp:bfsLayer
|
6
|